<ul><li>On May 6, 2024, the U.S. FDA completed its first AI-assisted scientific review to streamline review time and reduce manual analysis in healthcare.</li><li>The FDA's adoption of AI internally signifies a shift in how institutions view intelligence, incorporating it into healthcare workflows beyond being a diagnostic or triage tool.</li><li>In Asia, where AI adoption in healthcare is still in its early stages, the FDA's AI integration highlights the importance of building systems ready for AI, not just utilizing AI tools.</li><li>Three suggested actions for emerging systems include building regulatory readiness, focusing on workflows, and leapfrogging to create AI-integrated health systems from the ground up.</li></ul>

When the FDA Starts Using AI, What Should the Rest of the World Be Thinking?

Discover more